The global Wet Macular Degeneration market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Wet Macular Degeneration, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Wet Macular Degeneration.

Report Scope

The Wet Macular Degeneration market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Wet Macular Degeneration market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Wet Macular Degeneration companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Wet Macular Degeneration Market Report

Report Metric	Details
Report Name	Wet Macular Degeneration Market
CAGR	5%
Segment by Type	by Drug Lucentis Eylea Avastin Others by Route of Administration Intravitreal Intravenous
Segment by Application	Hospitals Clinics Research Institutes Academic Institutes
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Pfizer Inc., F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc., Novartis AG, Bausch Health Companies Inc., Apellis Pharmaceuticals Inc., GlaxoSmithKline plc, Ophthotech Corporation, Gilead Sciences, Inc., Alcon, Genzyme Corporation, Boehringer Ingelheim GmbH, EyeGate Pharmaceuticals, Inc., EyeCyte, Inc., PanOptica Inc
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Wet Macular Degeneration companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Wet Macular Degeneration Market report?

Ans: The main players in the Wet Macular Degeneration Market are Pfizer Inc., F. Hoffmann-La Roche AG, Regeneron Pharmaceuticals, Inc., Novartis AG, Bausch Health Companies Inc., Apellis Pharmaceuticals Inc., GlaxoSmithKline plc, Ophthotech Corporation, Gilead Sciences, Inc., Alcon, Genzyme Corporation, Boehringer Ingelheim GmbH, EyeGate Pharmaceuticals, Inc., EyeCyte, Inc., PanOptica Inc

What are the Application segmentation covered in the Wet Macular Degeneration Market report?

Ans: The Applications covered in the Wet Macular Degeneration Market report are Hospitals, Clinics, Research Institutes, Academic Institutes

What are the Type segmentation covered in the Wet Macular Degeneration Market report?

Ans: The Types covered in the Wet Macular Degeneration Market report are by Drug, Lucentis, Eylea, Avastin, Others, by Route of Administration, Intravitreal, Intravenous

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Drug

1.2.1 Global Wet Macular Degeneration Market Size Growth Rate by Drug: 2019 VS 2023 VS 2030

1.2.2 Lucentis

1.2.3 Eylea

1.2.4 Avastin

1.2.5 Others

1.3 Market by Application

1.3.1 Global Wet Macular Degeneration Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Research Institutes

1.3.5 Academic Institutes

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2 Global Growth Trends

2.1 Global Wet Macular Degeneration Market Perspective (2019-2030)

2.2 Wet Macular Degeneration Growth Trends by Region

2.2.1 Global Wet Macular Degeneration Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Wet Macular Degeneration Historic Market Size by Region (2019-2024)

2.2.3 Wet Macular Degeneration Forecasted Market Size by Region (2025-2030)

2.3 Wet Macular Degeneration Market Dynamics

2.3.1 Wet Macular Degeneration Industry Trends

2.3.2 Wet Macular Degeneration Market Drivers

2.3.3 Wet Macular Degeneration Market Challenges

2.3.4 Wet Macular Degeneration Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Wet Macular Degeneration Players by Revenue

3.1.1 Global Top Wet Macular Degeneration Players by Revenue (2019-2024)

3.1.2 Global Wet Macular Degeneration Revenue Market Share by Players (2019-2024)

3.2 Global Wet Macular Degeneration Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Wet Macular Degeneration Revenue

3.4 Global Wet Macular Degeneration Market Concentration Ratio

3.4.1 Global Wet Macular Degeneration Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Wet Macular Degeneration Revenue in 2023

3.5 Wet Macular Degeneration Key Players Head office and Area Served

3.6 Key Players Wet Macular Degeneration Product Solution and Service

3.7 Date of Enter into Wet Macular Degeneration Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Wet Macular Degeneration Breakdown Data by Type

4.1 Global Wet Macular Degeneration Historic Market Size by Type (2019-2024)

4.2 Global Wet Macular Degeneration Forecasted Market Size by Type (2025-2030)

5 Wet Macular Degeneration Breakdown Data by Application

5.1 Global Wet Macular Degeneration Historic Market Size by Application (2019-2024)

5.2 Global Wet Macular Degeneration Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Wet Macular Degeneration Market Size (2019-2030)

6.2 North America Wet Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Wet Macular Degeneration Market Size by Country (2019-2024)

6.4 North America Wet Macular Degeneration Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Wet Macular Degeneration Market Size (2019-2030)

7.2 Europe Wet Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Wet Macular Degeneration Market Size by Country (2019-2024)

7.4 Europe Wet Macular Degeneration Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Wet Macular Degeneration Market Size (2019-2030)

8.2 Asia-Pacific Wet Macular Degeneration Market Growth Rate by Region: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Wet Macular Degeneration Market Size by Region (2019-2024)

8.4 Asia-Pacific Wet Macular Degeneration Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Wet Macular Degeneration Market Size (2019-2030)

9.2 Latin America Wet Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Wet Macular Degeneration Market Size by Country (2019-2024)

9.4 Latin America Wet Macular Degeneration Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Wet Macular Degeneration Market Size (2019-2030)

10.2 Middle East & Africa Wet Macular Degeneration Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Wet Macular Degeneration Market Size by Country (2019-2024)

10.4 Middle East & Africa Wet Macular Degeneration Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Pfizer Inc.

11.1.1 Pfizer Inc. Company Detail

11.1.2 Pfizer Inc. Business Overview

11.1.3 Pfizer Inc. Wet Macular Degeneration Introduction

11.1.4 Pfizer Inc. Revenue in Wet Macular Degeneration Business (2019-2024)

11.1.5 Pfizer Inc. Recent Development

11.2 F. Hoffmann-La Roche AG

11.2.1 F. Hoffmann-La Roche AG Company Detail

11.2.2 F. Hoffmann-La Roche AG Business Overview

11.2.3 F. Hoffmann-La Roche AG Wet Macular Degeneration Introduction

11.2.4 F. Hoffmann-La Roche AG Revenue in Wet Macular Degeneration Business (2019-2024)

11.2.5 F. Hoffmann-La Roche AG Recent Development

11.3 Regeneron Pharmaceuticals, Inc.

11.3.1 Regeneron Pharmaceuticals, Inc. Company Detail

11.3.2 Regeneron Pharmaceuticals, Inc. Business Overview

11.3.3 Regeneron Pharmaceuticals, Inc. Wet Macular Degeneration Introduction

11.3.4 Regeneron Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2019-2024)

11.3.5 Regeneron Pharmaceuticals, Inc. Recent Development

11.4 Novartis AG

11.4.1 Novartis AG Company Detail

11.4.2 Novartis AG Business Overview

11.4.3 Novartis AG Wet Macular Degeneration Introduction

11.4.4 Novartis AG Revenue in Wet Macular Degeneration Business (2019-2024)

11.4.5 Novartis AG Recent Development

11.5 Bausch Health Companies Inc.

11.5.1 Bausch Health Companies Inc. Company Detail

11.5.2 Bausch Health Companies Inc. Business Overview

11.5.3 Bausch Health Companies Inc. Wet Macular Degeneration Introduction

11.5.4 Bausch Health Companies Inc. Revenue in Wet Macular Degeneration Business (2019-2024)

11.5.5 Bausch Health Companies Inc. Recent Development

11.6 Apellis Pharmaceuticals Inc.

11.6.1 Apellis Pharmaceuticals Inc. Company Detail

11.6.2 Apellis Pharmaceuticals Inc. Business Overview

11.6.3 Apellis Pharmaceuticals Inc. Wet Macular Degeneration Introduction

11.6.4 Apellis Pharmaceuticals Inc. Revenue in Wet Macular Degeneration Business (2019-2024)

11.6.5 Apellis Pharmaceuticals Inc. Recent Development

11.7 GlaxoSmithKline plc

11.7.1 GlaxoSmithKline plc Company Detail

11.7.2 GlaxoSmithKline plc Business Overview

11.7.3 GlaxoSmithKline plc Wet Macular Degeneration Introduction

11.7.4 GlaxoSmithKline plc Revenue in Wet Macular Degeneration Business (2019-2024)

11.7.5 GlaxoSmithKline plc Recent Development

11.8 Ophthotech Corporation

11.8.1 Ophthotech Corporation Company Detail

11.8.2 Ophthotech Corporation Business Overview

11.8.3 Ophthotech Corporation Wet Macular Degeneration Introduction

11.8.4 Ophthotech Corporation Revenue in Wet Macular Degeneration Business (2019-2024)

11.8.5 Ophthotech Corporation Recent Development

11.9 Gilead Sciences, Inc.

11.9.1 Gilead Sciences, Inc. Company Detail

11.9.2 Gilead Sciences, Inc. Business Overview

11.9.3 Gilead Sciences, Inc. Wet Macular Degeneration Introduction

11.9.4 Gilead Sciences, Inc. Revenue in Wet Macular Degeneration Business (2019-2024)

11.9.5 Gilead Sciences, Inc. Recent Development

11.10 Alcon

11.10.1 Alcon Company Detail

11.10.2 Alcon Business Overview

11.10.3 Alcon Wet Macular Degeneration Introduction

11.10.4 Alcon Revenue in Wet Macular Degeneration Business (2019-2024)

11.10.5 Alcon Recent Development

11.11 Genzyme Corporation

11.11.1 Genzyme Corporation Company Detail

11.11.2 Genzyme Corporation Business Overview

11.11.3 Genzyme Corporation Wet Macular Degeneration Introduction

11.11.4 Genzyme Corporation Revenue in Wet Macular Degeneration Business (2019-2024)

11.11.5 Genzyme Corporation Recent Development

11.12 Boehringer Ingelheim GmbH

11.12.1 Boehringer Ingelheim GmbH Company Detail

11.12.2 Boehringer Ingelheim GmbH Business Overview

11.12.3 Boehringer Ingelheim GmbH Wet Macular Degeneration Introduction

11.12.4 Boehringer Ingelheim GmbH Revenue in Wet Macular Degeneration Business (2019-2024)

11.12.5 Boehringer Ingelheim GmbH Recent Development

11.13 EyeGate Pharmaceuticals, Inc.

11.13.1 EyeGate Pharmaceuticals, Inc. Company Detail

11.13.2 EyeGate Pharmaceuticals, Inc. Business Overview

11.13.3 EyeGate Pharmaceuticals, Inc. Wet Macular Degeneration Introduction

11.13.4 EyeGate Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2019-2024)

11.13.5 EyeGate Pharmaceuticals, Inc. Recent Development

11.14 EyeCyte, Inc.

11.14.1 EyeCyte, Inc. Company Detail

11.14.2 EyeCyte, Inc. Business Overview

11.14.3 EyeCyte, Inc. Wet Macular Degeneration Introduction

11.14.4 EyeCyte, Inc. Revenue in Wet Macular Degeneration Business (2019-2024)

11.14.5 EyeCyte, Inc. Recent Development

11.15 PanOptica Inc

11.15.1 PanOptica Inc Company Detail

11.15.2 PanOptica Inc Business Overview

11.15.3 PanOptica Inc Wet Macular Degeneration Introduction

11.15.4 PanOptica Inc Revenue in Wet Macular Degeneration Business (2019-2024)

11.15.5 PanOptica Inc Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

FEATURED COMPANIES

Pfizer Inc

F. Hoffmann-La Roche AG

Regeneron Pharmaceuticals Inc

Novartis

Bausch Health Companies Inc.

Apellis Pharmaceuticals Inc

GlaxoSmithKline PLC

Ophthotech Corporation

Gilead Sciences Inc

Alcon

Genzyme Corporation

Boehringer Ingelheim GmbH

Eyegate Pharmaceuticals Inc.

EyeCyte, Inc.

PanOptica Inc

List of Tables

Table 1. Global Wet Macular Degeneration Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of Lucentis

Table 3. Key Players of Eylea

Table 4. Key Players of Avastin

Table 5. Key Players of Others

Table 6. Global Wet Macular Degeneration Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 7. Global Wet Macular Degeneration Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 8. Global Wet Macular Degeneration Market Size by Region (2019-2024) & (US$ Million)

Table 9. Global Wet Macular Degeneration Market Share by Region (2019-2024)

Table 10. Global Wet Macular Degeneration Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 11. Global Wet Macular Degeneration Market Share by Region (2025-2030)

Table 12. Wet Macular Degeneration Market Trends

Table 13. Wet Macular Degeneration Market Drivers

Table 14. Wet Macular Degeneration Market Challenges

Table 15. Wet Macular Degeneration Market Restraints

Table 16. Global Wet Macular Degeneration Revenue by Players (2019-2024) & (US$ Million)

Table 17. Global Wet Macular Degeneration Market Share by Players (2019-2024)

Table 18. Global Top Wet Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Wet Macular Degeneration as of 2023)

Table 19. Ranking of Global Top Wet Macular Degeneration Companies by Revenue (US$ Million) in 2023

Table 20. Global 5 Largest Players Market Share by Wet Macular Degeneration Revenue (CR5 and HHI) & (2019-2024)

Table 21. Key Players Headquarters and Area Served

Table 22. Key Players Wet Macular Degeneration Product Solution and Service

Table 23. Date of Enter into Wet Macular Degeneration Market

Table 24. Mergers & Acquisitions, Expansion Plans

Table 25. Global Wet Macular Degeneration Market Size by Type (2019-2024) & (US$ Million)

Table 26. Global Wet Macular Degeneration Revenue Market Share by Type (2019-2024)

Table 27. Global Wet Macular Degeneration Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 28. Global Wet Macular Degeneration Revenue Market Share by Type (2025-2030)

Table 29. Global Wet Macular Degeneration Market Size by Application (2019-2024) & (US$ Million)

Table 30. Global Wet Macular Degeneration Revenue Market Share by Application (2019-2024)

Table 31. Global Wet Macular Degeneration Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 32. Global Wet Macular Degeneration Revenue Market Share by Application (2025-2030)

Table 33. North America Wet Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 34. North America Wet Macular Degeneration Market Size by Country (2019-2024) & (US$ Million)

Table 35. North America Wet Macular Degeneration Market Size by Country (2025-2030) & (US$ Million)

Table 36. Europe Wet Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 37. Europe Wet Macular Degeneration Market Size by Country (2019-2024) & (US$ Million)

Table 38. Europe Wet Macular Degeneration Market Size by Country (2025-2030) & (US$ Million)

Table 39. Asia-Pacific Wet Macular Degeneration Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030

Table 40. Asia-Pacific Wet Macular Degeneration Market Size by Region (2019-2024) & (US$ Million)

Table 41. Asia-Pacific Wet Macular Degeneration Market Size by Region (2025-2030) & (US$ Million)

Table 42. Latin America Wet Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 43. Latin America Wet Macular Degeneration Market Size by Country (2019-2024) & (US$ Million)

Table 44. Latin America Wet Macular Degeneration Market Size by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Wet Macular Degeneration Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 46. Middle East & Africa Wet Macular Degeneration Market Size by Country (2019-2024) & (US$ Million)

Table 47. Middle East & Africa Wet Macular Degeneration Market Size by Country (2025-2030) & (US$ Million)

Table 48. Pfizer Inc. Company Detail

Table 49. Pfizer Inc. Business Overview

Table 50. Pfizer Inc. Wet Macular Degeneration Product

Table 51. Pfizer Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 52. Pfizer Inc. Recent Development

Table 53. F. Hoffmann-La Roche AG Company Detail

Table 54. F. Hoffmann-La Roche AG Business Overview

Table 55. F. Hoffmann-La Roche AG Wet Macular Degeneration Product

Table 56. F. Hoffmann-La Roche AG Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 57. F. Hoffmann-La Roche AG Recent Development

Table 58. Regeneron Pharmaceuticals, Inc. Company Detail

Table 59. Regeneron Pharmaceuticals, Inc. Business Overview

Table 60. Regeneron Pharmaceuticals, Inc. Wet Macular Degeneration Product

Table 61. Regeneron Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 62. Regeneron Pharmaceuticals, Inc. Recent Development

Table 63. Novartis AG Company Detail

Table 64. Novartis AG Business Overview

Table 65. Novartis AG Wet Macular Degeneration Product

Table 66. Novartis AG Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 67. Novartis AG Recent Development

Table 68. Bausch Health Companies Inc. Company Detail

Table 69. Bausch Health Companies Inc. Business Overview

Table 70. Bausch Health Companies Inc. Wet Macular Degeneration Product

Table 71. Bausch Health Companies Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 72. Bausch Health Companies Inc. Recent Development

Table 73. Apellis Pharmaceuticals Inc. Company Detail

Table 74. Apellis Pharmaceuticals Inc. Business Overview

Table 75. Apellis Pharmaceuticals Inc. Wet Macular Degeneration Product

Table 76. Apellis Pharmaceuticals Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 77. Apellis Pharmaceuticals Inc. Recent Development

Table 78. GlaxoSmithKline plc Company Detail

Table 79. GlaxoSmithKline plc Business Overview

Table 80. GlaxoSmithKline plc Wet Macular Degeneration Product

Table 81. GlaxoSmithKline plc Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 82. GlaxoSmithKline plc Recent Development

Table 83. Ophthotech Corporation Company Detail

Table 84. Ophthotech Corporation Business Overview

Table 85. Ophthotech Corporation Wet Macular Degeneration Product

Table 86. Ophthotech Corporation Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 87. Ophthotech Corporation Recent Development

Table 88. Gilead Sciences, Inc. Company Detail

Table 89. Gilead Sciences, Inc. Business Overview

Table 90. Gilead Sciences, Inc. Wet Macular Degeneration Product

Table 91. Gilead Sciences, Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 92. Gilead Sciences, Inc. Recent Development

Table 93. Alcon Company Detail

Table 94. Alcon Business Overview

Table 95. Alcon Wet Macular Degeneration Product

Table 96. Alcon Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 97. Alcon Recent Development

Table 98. Genzyme Corporation Company Detail

Table 99. Genzyme Corporation Business Overview

Table 100. Genzyme Corporation Wet Macular Degeneration Product

Table 101. Genzyme Corporation Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 102. Genzyme Corporation Recent Development

Table 103. Boehringer Ingelheim GmbH Company Detail

Table 104. Boehringer Ingelheim GmbH Business Overview

Table 105. Boehringer Ingelheim GmbH Wet Macular Degeneration Product

Table 106. Boehringer Ingelheim GmbH Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 107. Boehringer Ingelheim GmbH Recent Development

Table 108. EyeGate Pharmaceuticals, Inc. Company Detail

Table 109. EyeGate Pharmaceuticals, Inc. Business Overview

Table 110. EyeGate Pharmaceuticals, Inc. Wet Macular Degeneration Product

Table 111. EyeGate Pharmaceuticals, Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 112. EyeGate Pharmaceuticals, Inc. Recent Development

Table 113. EyeCyte, Inc. Company Detail

Table 114. EyeCyte, Inc. Business Overview

Table 115. EyeCyte, Inc. Wet Macular Degeneration Product

Table 116. EyeCyte, Inc. Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 117. EyeCyte, Inc. Recent Development

Table 118. PanOptica Inc Company Detail

Table 119. PanOptica Inc Business Overview

Table 120. PanOptica Inc Wet Macular Degeneration Product

Table 121. PanOptica Inc Revenue in Wet Macular Degeneration Business (2019-2024) & (US$ Million)

Table 122. PanOptica Inc Recent Development

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

List of Figures

Figure 1. Global Wet Macular Degeneration Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 2. Global Wet Macular Degeneration Market Share by Type: 2023 VS 2030

Figure 3. Lucentis Features

Figure 4. Eylea Features

Figure 5. Avastin Features

Figure 6. Others Features

Figure 7. Global Wet Macular Degeneration Market Size Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Wet Macular Degeneration Market Share by Application: 2023 VS 2030

Figure 9. Hospitals Case Studies

Figure 10. Clinics Case Studies

Figure 11. Research Institutes Case Studies

Figure 12. Academic Institutes Case Studies

Figure 13. Wet Macular Degeneration Report Years Considered

Figure 14. Global Wet Macular Degeneration Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 15. Global Wet Macular Degeneration Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Wet Macular Degeneration Market Share by Region: 2023 VS 2030

Figure 17. Global Wet Macular Degeneration Market Share by Players in 2023

Figure 18. Global Top Wet Macular Degeneration Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Wet Macular Degeneration as of 2023)

Figure 19. The Top 10 and 5 Players Market Share by Wet Macular Degeneration Revenue in 2023

Figure 20. North America Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 21. North America Wet Macular Degeneration Market Share by Country (2019-2030)

Figure 22. United States Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Canada Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 25. Europe Wet Macular Degeneration Market Share by Country (2019-2030)

Figure 26. Germany Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. France Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. U.K. Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Italy Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Russia Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Nordic Countries Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 33. Asia-Pacific Wet Macular Degeneration Market Share by Region (2019-2030)

Figure 34. China Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. Japan Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. South Korea Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. Southeast Asia Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. India Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Australia Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 41. Latin America Wet Macular Degeneration Market Share by Country (2019-2030)

Figure 42. Mexico Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Brazil Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 45. Middle East & Africa Wet Macular Degeneration Market Share by Country (2019-2030)

Figure 46. Turkey Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. Saudi Arabia Wet Macular Degeneration Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Pfizer Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 49. F. Hoffmann-La Roche AG Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 50. Regeneron Pharmaceuticals, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 51. Novartis AG Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 52. Bausch Health Companies Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 53. Apellis Pharmaceuticals Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 54. GlaxoSmithKline plc Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 55. Ophthotech Corporation Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 56. Gilead Sciences, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 57. Alcon Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 58. Genzyme Corporation Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 59. Boehringer Ingelheim GmbH Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 60. EyeGate Pharmaceuticals, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 61. EyeCyte, Inc. Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 62. PanOptica Inc Revenue Growth Rate in Wet Macular Degeneration Business (2019-2024)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions